Matrix metalloproteinase 2 inhibition: combined quantum mechanics and molecular mechanics studies of the inhibition mechanism of (4-phenoxyphenylsulfonyl)methylthiirane and its oxirane analogue.
暂无分享,去创建一个
Thom Vreven | Peng Tao | H. Schlegel | T. Vreven | Peng Tao | S. Mobashery | J. Fisher | H Bernhard Schlegel | Jed F Fisher | Qicun Shi | Shahriar Mobashery | Q. Shi | H. Bernhard Schlegel
[1] P. Kollman,et al. A well-behaved electrostatic potential-based method using charge restraints for deriving atomic char , 1993 .
[2] Feliu Maseras,et al. IMOMM: A new integrated ab initio + molecular mechanics geometry optimization scheme of equilibrium structures and transition states , 1995, J. Comput. Chem..
[3] Kenneth M. Merz,et al. Force Field Design for Metalloproteins , 1991 .
[4] G. Smith,et al. Ovarian tissue remodeling: role of matrix metalloproteinases and their inhibitors , 2002, Molecular and Cellular Endocrinology.
[5] Akash Khandelwal,et al. QM/MM linear response method distinguishes ligand affinities for closely related metalloproteins , 2007, Proteins.
[6] Thom Vreven,et al. Model studies of the structures, reacitivities, and reaction mechanisms of metalloenzymes , 2001, IBM J. Res. Dev..
[7] K. Morokuma,et al. ONIOM: A Multilayered Integrated MO + MM Method for Geometry Optimizations and Single Point Energy Predictions. A Test for Diels−Alder Reactions and Pt(P(t-Bu)3)2 + H2 Oxidative Addition , 1996 .
[8] L. Liotta,et al. Partial purification and characterization of a neutral protease which cleaves type IV collagen. , 1981, Biochemistry.
[9] Thom Vreven,et al. Transition States in a Protein Environment - ONIOM QM:MM Modeling of Isopenicillin N Synthesis. , 2009, Journal of chemical theory and computation.
[10] S. Meroueh,et al. Synthesis of chiral 2-(4-phenoxyphenylsulfonylmethyl)thiiranes as selective gelatinase inhibitors. , 2005, Organic letters.
[11] P. Kollman,et al. Application of RESP charges to calculate conformational energies, hydrogen bond energies, and free energies of solvation , 1993 .
[12] Robert Huber,et al. Crystal structures of MMP-9 complexes with five inhibitors: contribution of the flexible Arg424 side-chain to selectivity. , 2007, Journal of molecular biology.
[13] Tom L. Blundell,et al. X-RAY STRUCTURE OF GELATINASE A CATALYTIC DOMAIN COMPLEXED WITH A HYDROXAMATE INHIBITOR , 1999 .
[14] S. Meroueh,et al. Molecular structures and dynamics of the stepwise activation mechanism of a matrix metalloproteinase zymogen: challenging the cysteine switch dogma. , 2007, Journal of the American Chemical Society.
[15] K. Morokuma,et al. Computational insights into the mechanism of radical generation in B12-dependent methylmalonyl-CoA mutase. , 2006, Journal of the American Chemical Society.
[16] Thom Vreven,et al. Geometry optimization with QM/MM, ONIOM, and other combined methods. I. Microiterations and constraints , 2003, J. Comput. Chem..
[17] S. Mobashery,et al. Conformational analyses of thiirane-based gelatinase inhibitors. , 2008, Bioorganic & medicinal chemistry letters.
[18] R. Schulz,et al. Pimecrolimus: a review , 2022 .
[19] M. Frisch,et al. CASSCF calculations for photoinduced processes in large molecules: Choosing when to use the RASSCF, ONIOM and MMVB approximations , 2007 .
[20] M. Bernardo,et al. Potent Mechanism-based Inhibitors for Matrix Metalloproteinases* , 2005, Journal of Biological Chemistry.
[21] K. Morokuma,et al. On the application of the IMOMO (integrated molecular orbital + molecular orbital) method , 2000 .
[22] F. Diederich,et al. Starving the malaria parasite: inhibitors active against the aspartic proteases plasmepsins I, II, and IV. , 2006, Angewandte Chemie.
[23] Keiji Morokuma,et al. The IMOMO method: Integration of different levels of molecular orbital approximations for geometry optimization of large systems: Test for n‐butane conformation and SN2 reaction: RCl+Cl− , 1996 .
[24] G. Schneider,et al. Structure of human pro-matrix metalloproteinase-2: activation mechanism revealed. , 1999, Science.
[25] C. Janson,et al. Structure of the C-terminally truncated human ProMMP9, a gelatin-binding matrix metalloproteinase. , 2002, Acta crystallographica. Section D, Biological crystallography.
[26] Peng Tao,et al. DFT studies of the ring-opening mechanism of SB-3CT, a potent inhibitor of matrix metalloproteinase 2. , 2009, Organic Letters.
[27] J. McEwan,et al. Matrix metalloproteinases and cardiovascular disease. , 1995, Circulation research.
[28] S. Mobashery,et al. Recent advances in MMP inhibitor design , 2006, Cancer and Metastasis Reviews.
[29] Yunbo Shi,et al. Regulation of extracellular matrix remodeling and cell fate determination by matrix metalloproteinase stromelysin-3 during thyroid hormone-dependent post-embryonic development. , 2007, Pharmacology & therapeutics.
[30] V. Kähäri,et al. Matrix metalloproteinases in cancer: Prognostic markers and therapeutic targets , 2002, International journal of cancer.
[31] R. Fridman,et al. Active Site Ring‐Opening of a Thiirane Moiety and Picomolar Inhibition of Gelatinases , 2009, Chemical biology & drug design.
[32] A. Noël,et al. Matrix metalloproteinases at cancer tumor-host interface. , 2008, Seminars in cell & developmental biology.
[33] Ping-Heng Tan,et al. Distinct roles of matrix metalloproteases in the early- and late-phase development of neuropathic pain , 2008, Nature Medicine.
[34] F. Luft. Matrix metalloproteinases and their regulators are cardiovascular therapeutic targets , 2004, Journal of Molecular Medicine.
[35] P. Kollman,et al. A Second Generation Force Field for the Simulation of Proteins, Nucleic Acids, and Organic Molecules , 1995 .
[36] Z. Werb,et al. New functions for the matrix metalloproteinases in cancer progression , 2002, Nature Reviews Cancer.
[37] S. Meroueh,et al. Structural Basis for Potent Slow Binding Inhibition of Human Matrix Metalloproteinase-2 (MMP-2)* , 2003, Journal of Biological Chemistry.
[38] Thom Vreven,et al. Combining Quantum Mechanics Methods with Molecular Mechanics Methods in ONIOM. , 2006, Journal of chemical theory and computation.
[39] Holger Gohlke,et al. The Amber biomolecular simulation programs , 2005, J. Comput. Chem..
[40] K. Morokuma,et al. A NEW ONIOM IMPLEMENTATION IN GAUSSIAN98. PART I. THE CALCULATION OF ENERGIES, GRADIENTS, VIBRATIONAL FREQUENCIES AND ELECTRIC FIELD DERIVATIVES , 1999 .
[41] L. Coussens,et al. Matrix metalloproteinases and the development of cancer. , 1996, Chemistry & biology.
[42] W. Stallings,et al. Solution structure and backbone dynamics of the catalytic domain of matrix metalloproteinase-2 complexed with a hydroxamic acid inhibitor. , 2002, Biochimica et biophysica acta.
[43] S. Janssens,et al. What has been learned about the cardiovascular effects of matrix metalloproteinases from mouse models? , 2006, Cardiovascular research.
[44] L. Kotra,et al. Potent and Selective Mechanism-Based Inhibition of Gelatinases , 2000 .
[45] Satya P. Gupta,et al. Quantitative structure-activity relationship studies on zinc-containing metalloproteinase inhibitors. , 2007, Chemical reviews.
[46] Katie M. Reindl,et al. Quantitative characterization of binding of small molecules to extracellular matrix. , 2006, Journal of biochemical and biophysical methods.
[47] J. Woessner,et al. Matrix metalloproteinases and their inhibitors in connective tissue remodeling , 1991, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[48] D. Suárez,et al. Molecular dynamics simulations of the active matrix metalloproteinase‐2: Positioning of the N‐terminal fragment and binding of a small peptide substrate , 2008, Proteins.
[49] Thom Vreven,et al. Geometry optimization with QM/MM methods II: Explicit quadratic coupling , 2006 .
[50] G. Homandberg,et al. Hyaluronan enhances cartilage repair through low grade tissue remodeling involving cytokines and matrix metalloproteinases , 2004, Inflammation Research.
[51] K. Morokuma,et al. Is the protein surrounding the active site critical for hydrogen peroxide reduction by selenoprotein glutathione peroxidase? An ONIOM study. , 2006, The journal of physical chemistry. B.
[52] V. Lukacova,et al. A comparison of the binding sites of matrix metalloproteinases and tumor necrosis factor-alpha converting enzyme: implications for selectivity. , 2005, Journal of medicinal chemistry.
[53] Y. Itoh,et al. Matrix metalloproteinases in cancer. , 2002, Essays in biochemistry.
[54] E. Furth,et al. Induction of matrix metalloproteinases and collagenolysis in chick embryonic membranes before hatching. , 1999, Biology of reproduction.
[55] Todd J. A. Ewing,et al. Critical evaluation of search algorithms for automated molecular docking and database screening , 1997, J. Comput. Chem..
[56] Viera Lukacova,et al. Binding of Matrix Metalloproteinase Inhibitors to Extracellular Matrix: 3D‐QSAR Analysis , 2008, Chemical biology & drug design.
[57] Akash Khandelwal,et al. Improved estimation of ligand–macromolecule binding affinities by linear response approach using a combination of multi-mode MD simulation and QM/MM methods , 2007, J. Comput. Aided Mol. Des..
[58] Chi-Hsien Liu,et al. Characterization of matrix metalloproteinase expressed by human embryonic kidney cells , 2006, Biotechnology Letters.
[59] Soumyendu Raha,et al. Similarity of Binding Sites of Human Matrix Metalloproteinases*[boxs] , 2004, Journal of Biological Chemistry.